-       Report 
   - March 2025
    -  200 Pages 
    Global
   
   From       €4029EUR$4,490USD£3,536GBP 
                -       Report 
   - February 2025
    -  200 Pages 
    Global
   
   From       €4029EUR$4,490USD£3,536GBP 
                -       Report 
   - February 2025
    -  200 Pages 
    Global
   
   From       €4029EUR$4,490USD£3,536GBP 
                -       Report 
   - January 2025
    -  175 Pages 
    Global
   
   From       €4029EUR$4,490USD£3,536GBP 
                -       Report 
   - November 2025
    -  368 Pages 
    Global
   
   From       €5249EUR$5,850USD£4,607GBP 
                 -       Report 
   - November 2025
    -  383 Pages 
    Global
   
   From       €5249EUR$5,850USD£4,607GBP 
                -       Report 
   - November 2025
    -  368 Pages 
    Global
   
   From       €5249EUR$5,850USD£4,607GBP 
                -       Report 
   - November 2025
    -  297 Pages 
    Global
   
   From       €5249EUR$5,850USD£4,607GBP 
                -       Report 
   - November 2025
    -  171 Pages 
    Global
   
   From       €5249EUR$5,850USD£4,607GBP 
                -       Report 
   - November 2025
    -  250 Pages 
    Global
   
   From       €5249EUR$5,850USD£4,607GBP 
                -       Report 
   - September 2025
    -  250 Pages 
    Global
   
   From       €4029EUR$4,490USD£3,536GBP 
                  -       Report 
   - April 2025
    -  200 Pages 
    Global
   
   From       €5707EUR$6,360USD£5,009GBP 
      €7134EUR$7,950USD£6,261GBP 
                  -       Clinical Trials 
   - July 2025
    -  280 Pages 
    Global
   
   From       €2154EUR$2,400USD£1,890GBP 
      €2692EUR$3,000USD£2,363GBP 
                  -       Drug Pipelines 
   - April 2025
    -  80 Pages 
    Global
   
   From       €1436EUR$1,600USD£1,260GBP 
      €1795EUR$2,000USD£1,575GBP 
                  -       Clinical Trials 
   - April 2025
    -  60 Pages 
    Global
   
   From       €1077EUR$1,200USD£945GBP 
      €1346EUR$1,500USD£1,181GBP 
                  -       Clinical Trials 
   - April 2025
    -  40 Pages 
    Global
   
   From       €897EUR$1,000USD£788GBP 
      €1122EUR$1,250USD£984GBP 
                  -       Clinical Trials 
   - April 2025
    -  60 Pages 
    Global
   
   From       €897EUR$1,000USD£788GBP 
      €1122EUR$1,250USD£984GBP 
                -       Report 
   - October 2025
     Global
   
   From       €4397EUR$4,900USD£3,859GBP 
                -       Report 
   - July 2025
     Global
   
   From       €4397EUR$4,900USD£3,859GBP 
                -       Report 
   - April 2025
     Global
   
   From       €4397EUR$4,900USD£3,859GBP 
             
         Somatostatin is a peptide hormone that is used in the treatment of various types of cancer. It is used to inhibit the release of growth hormones, which can help reduce the size of tumors. It is also used to reduce the side effects of chemotherapy and radiation therapy. Somatostatin is available in both injectable and oral forms. It is often used in combination with other drugs to treat cancer.
Somatostatin is used to treat a variety of cancers, including pancreatic, prostate, and neuroendocrine    tumors. It is also used to treat acromegaly, a condition caused by excessive growth hormone production. Somatostatin is also used to treat Cushing's syndrome, a condition caused by excessive cortisol production.
Some companies that produce somatostatin include Novartis, Merck, and Pfizer. Other companies that produce somatostatin-based drugs include Ipsen, Teva, and Sandoz. Show Less   Read more